Quarterly results and guidance from the drugmakers that matter.
MeiraGTx says its dossier for the X-linked retinitis pigmentosa gene therapy is complete, with a European filing planned for December 2026 and a US submission early next year.
Ascendis Pharma reported strong third-quarter growth led by YORVIPATH and said the CHMP and COMP have issued positive opinions for TransCon CNP in paediatric achondroplasia.
Monopar Therapeutics says it expects to finish its rolling FDA submission for ALXN1840 within weeks, reporting $129.4 million in cash that it says funds operations through at least March 2028.
Ascendis Pharma reported an operating profit of €125 million for Q3 2026 and a positive CHMP opinion for TransCon CNP, with an EU decision expected in Q4.
The Dutch RNA therapeutics company reports higher cash and equity in unaudited IFRS interim statements that refer to a June public offering and its Eli Lilly collaboration.
The Israeli wound-care company reports a $6.0M quarterly net loss, a clean DSMB review and successful GMP inspections, while 2026 revenue hinges on uncertain US government funding.
The Icelandic biosimilar maker reported adjusted revenue of $323.4M for the first nine months of 2026 and now expects full-year results toward the lower end of guidance.
The Nasdaq-listed botanical synthesis company reports lower cash at $12.5M and a September 2026 dual listing on the Tel Aviv Stock Exchange.
Pelthos Therapeutics reports third-quarter Zelsuvmi sales of $15.2M, wider commercial coverage, an enlarged Horizon loan and an expected Q1 2027 close for its Castle Creek deal.
The US CBD maker reports its smallest operating loss since 2019 and warns that a federal hemp restriction taking effect on 11 December could cover its full-spectrum products.
The Icelandic biosimilar maker reports $323.4M adjusted revenue to September, keeps its full-year guidance, but now expects to land towards the lower end of the range.
The Hungarian drugmaker reports reported pharma revenue up 2.6% to HUF 686.5bn despite a roughly 9-point currency drag, and raises its full-year outlook.
The Danish drugmaker now expects 11-12% revenue growth and 15-19% adjusted EBITDA growth at constant exchange rates, citing strong US Vyepti sales and stronger Partner Markets.
Legend Biotech posted third-quarter CARVYKTI net trade sales of about $710 million and operating income of $46.8 million, and said the FDA cleared its IND for CD19/CD20 in vivo CAR-T LB2501.
Alcon reports 10% higher third-quarter net income, while a $505m charge for discontinuing PowerVision intraocular lens programmes drives a 35% fall in nine-month operating income.
The Deep TMS maker reported operating income of $2.6m and 130 systems shipped, and expects full-year 2026 results at the upper end of its guidance.
The T-cell receptor therapeutics company reports higher research costs and a warrant liability charge, while holding cash and other financial assets of roughly €472M at 30 September.
The company's MD&A for the period to 30 September 2026 points to EP-104GI in eosinophilic esophagitis, with FDA-required trials ahead, and a search for funding or a partner for osteoarthritis.
The Nasdaq-listed metal 3D printing firm reports higher cash, lower debt and a revised gross margin outlook, and says it has opened its Forge 1 production campus.
The US company says net sales of its NPM1-mutated AML therapy rose 53%, and it has agreed a registrational design with the FDA for darlifarnib in HRAS-mutant salivary gland cancer.
The US dermatology company's third-quarter results show first revenue from an online cosmetic product, $5.0 million in cash and a new acne trial ahead of a planned 2027 launch.
The life-sciences tools supplier posted 5% revenue growth and a $158M net loss after a $149M impairment, and forecast FY2027 revenue of $648-660M.
The wound-care device maker says a CMS proposed rule on skin substitute pricing and CPT code 97610 curbed Ultramist system sales, which fell to 40 units from 155.
The maker of the Freedom subcutaneous infusion system posted a small profit, improved its gross margin and trimmed its full-year revenue range while lowering its margin outlook.
CMS reversed its proposed nonpayment stance on QTscan diagnostic breast exams, while Middle East conflict delayed shipments and pushed the company to lower its full-year outlook.
Cumberland Pharmaceuticals plans an FDA submission after a pre-NDA meeting, and also reported Phase 2a systemic sclerosis data and Q3 net income lifted by the Apotex transaction.
The company, formerly Achieve Life Sciences, reported Q3 results and said it still expects possible FDA approval of its smoking cessation candidate by the end of Q2 2027.
The US firm's third-quarter revenue was driven mainly by licence income after the FDA approved its blood-based colorectal cancer screening test, which Abbott has since launched.
The cell-engineering company reported $10.2 million in third-quarter revenue and plans to buy a GMP-grade reagent supplier, partly funded by a $22 million credit facility draw.
The US company reported third-quarter TriNav revenue of $12.9 million, revised its 2026 guidance, and flagged an FDA clearance and final CMS payment changes for 2027.